<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00091585</url>
  </required_header>
  <id_info>
    <org_study_id>SPO-0001</org_study_id>
    <nct_id>NCT00091585</nct_id>
  </id_info>
  <brief_title>Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.</brief_title>
  <official_title>Phase I Open-Label, Multicenter, Dose-Escalation Clinical Study of the Initial Safety and Pharmacokinetic Profiles of Intravenous Administration of SNS-595 in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunesis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunesis Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether SNS-595 given intravenously once every 3&#xD;
      weeks is safe.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Other objectives of this study include measuring pharmacokinetics (how long the drug can be&#xD;
      measured in the blood) and determining the dose and dose schedule for the next phase of&#xD;
      studies with SNS-595.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date>November 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SNS-595</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must give written informed consent&#xD;
&#xD;
          -  18 years of age&#xD;
&#xD;
          -  Advanced solid malignant tumors&#xD;
&#xD;
          -  Tumor can be measured and evaluated&#xD;
&#xD;
          -  Blood tests are within standard limits&#xD;
&#xD;
          -  Normal blood coagulation&#xD;
&#xD;
          -  ECOG Performance Status equal to 0 or 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  Women of childbearing potential unwilling to use an approved, effective means of&#xD;
             contraception according to the institution's standards.&#xD;
&#xD;
          -  Heart attack, stroke/TIA or other blood clotting event (deep vein thrombosis or&#xD;
             pulmonary embolus) within 6 months before the screen visit.&#xD;
&#xD;
          -  Requires kidney dialysis (hemodialysis or peritoneal).&#xD;
&#xD;
          -  Known bleeding disorder (ie, hemophilia, von Willebrand Disease, coagulopathy, etc.).&#xD;
&#xD;
          -  Received an investigational agent or prior chemotherapy or immunotherapy within 28&#xD;
             days before first dose of SNS-595&#xD;
&#xD;
          -  Receiving therapeutic anticoagulation therapy (coumadin, heparin, etc.).&#xD;
&#xD;
          -  Currently receiving corticosteroids (inhaled steroids for breathing diseases are&#xD;
             allowed) or seizure medications.&#xD;
&#xD;
          -  Any medical, psychological, or social condition that, in the opinion of the Principal&#xD;
             Investigator, would contraindicate the patient's participation in the clinical trial&#xD;
             due to safety and or compliance with study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel C. Adelman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sunesis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>September 10, 2004</study_first_submitted>
  <study_first_submitted_qc>September 13, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2004</study_first_posted>
  <last_update_submitted>May 9, 2007</last_update_submitted>
  <last_update_submitted_qc>May 9, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2007</last_update_posted>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

